$14.26

+0.24 (+1.71%)

Weekly Expected Move ±7.0%

$12 $13 $14 $15 $16

NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 47 · $2.0B mcap · 138M float · 2.36% daily turnover · Short 62% of daily vol

Overview Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Analysis Technicals Weather Peers ESG Institutions ETF Exposure Dark Pool Short Interest Supply Chain

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue

$4.3B -2.8% ▼

5Y CAGR: +0.8%

Gross Profit

$1.5B -3.1% ▼

5Y CAGR: -0.0%

Operating Income

$343M +204.1% ▲

5Y CAGR: +5.3%

Net Income

-$1.4B -729.7% ▼

EPS (Diluted)

$-10.29 -723.2% ▼

EBITDA

-$798M -284.3% ▼

Profit Margins

Year-over-Year Growth

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$4.1B	$4.5B	$4.7B	$4.4B	$4.3B
YoY Growth	-18.3%	+7.6%	+4.6%	-6.1%	-2.8%
Cost of Revenue	$2.7B	$3.0B	$3.0B	$2.8B	$2.8B
Gross Profit	$1.4B	$1.5B	$1.7B	$1.5B	$1.5B
Gross Margin	34.2%	32.7%	36.1%	35.3%	35.1%
R&D Expenses	$122M	$123M	$122M	$112M	$95M
SG&A Expenses	$1.1B	$1.2B	$1.3B	$1.1B	$526M
Operating Expenses	$1.0B	$1.4B	$1.5B	$1.4B	$1.2B
Operating Income	$410M	$79M	$152M	$113M	$343M
Operating Margin	9.9%	1.8%	3.3%	2.6%	8.1%
Interest Expense	$125M	$156M	$174M	$188M	$162M
Income Before Tax	$259M	-$139M	-$8M	-$81M	-$1.3B
Tax Expense	$390M	-$8M	-$4M	$80M	$104M
Net Income	-$69M	-$141M	-$13M	-$172M	-$1.4B
Net Margin	-1.7%	-3.2%	-0.3%	-3.9%	-33.5%
EPS (Diluted)	$-0.98	$-0.97	$-0.09	$-1.25	$-10.29
EBITDA	$696M	$356M	$525M	$433M	-$798M
Shares Outstanding	134M	134M	135M	137M	138M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$1.1B	$1.1B	$1.0B	$1.1B	$1.0B	$1.1B	$969M	$1.0B
Cost of Revenue	$683M	$752M	$652M	$693M	$666M	$747M	$644M	$709M
Gross Profit	$404M	$386M	$392M	$363M	$377M	$362M	$326M	$314M
Gross Margin	37.2%	33.9%	37.6%	34.4%	36.1%	32.6%	33.6%	30.7%
R&D Expenses	$26M	$28M	$27M	$22M	$25M	$22M	$25M	$24M
SG&A Expenses	$272M	$235M	$281M	$273M	$222M	-$249M	$130M	$230M
Operating Expenses	$324M	$272M	$345M	$318M	$304M	$278M	$292M	$290M
Operating Income	$80M	$114M	$47M	$45M	$73M	$85M	$34M	$24M
Operating Margin	7.4%	10.0%	4.5%	4.3%	7.0%	7.6%	3.5%	2.3%
Interest Expense	$58M	$43M	$39M	$40M	$54M	$30M	$41M	$38M
Income Before Tax	$22M	$70M	$8M	$3M	$22M	-$1.3B	-$408M	$105M
Tax Expense	$39M	$112M	$8M	$4M	$10M	$83M	-$19M	$17M
Net Income	-$21M	-$44M	-$6M	-$8M	$8M	-$1.4B	-$399M	$74M
Net Margin	-1.9%	-3.9%	-0.6%	-0.8%	0.7%	-127.8%	-41.1%	7.3%
EPS (Diluted)	$-0.15	$-0.32	$-0.05	$-0.06	$0.05	$-10.23	$-2.87	$0.53
EBITDA	$162M	$193M	$127M	$129M	$162M	-$1.2B	-$284M	$144M
Shares Outstanding	138M	138M	138M	138M	139M	138M	139M	140M

PRGO NYSE